Literature DB >> 7836766

Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody.

R Yuan1, A Casadevall, G Spira, M D Scharff.   

Abstract

Passively administered mAbs to Cryptococcus neoformans capsular polysaccharide can alter the course of infection in mouse models. In preliminary studies of passive Ab efficacy, most IgM, IgA, and IgG1 mAbs were protective, but the few IgG3 mAbs tested did not confer significant protection. Because IgG3 is effective in pneumococcal infections, this phenomenon was examined more rigorously by generating an IgG1 switch variant from the non-protective IgG3 mAb 3E5 and comparing its protective efficacy in a murine model of i.v. infection by using strains of both the A and D serotypes. The 3E5 IgG3 mAb did not prolong survival or reduce organ fungal burden. Rather, the IgG3 decreased survival relative to controls. In contrast, the IgG1 switch variant of 3E5 significantly prolonged survival, reduced organ colony-forming units, and reduced serum polysaccharide Ag level in infected mice. The results establish that isotype is important for Ab efficacy against C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection.

Authors:  G M Winslow; E Yager; K Shilo; E Volk; A Reilly; F K Chu
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Basic problems of serological laboratory diagnosis.

Authors:  W Fierz
Journal:  Mol Biotechnol       Date:  1999-12-01       Impact factor: 2.695

Review 3.  Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.

Authors:  Arturo Casadevall
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

4.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 5.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

10.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.